Latest & greatest articles for breast cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on breast cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on breast cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for breast cancer

181. Small molecule biomarkers for the early detection of breast cancer: a systematic review

Small molecule biomarkers for the early detection of breast cancer: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites

2019 PROSPERO

182. Prevalence of co-morbidity and survival among breast cancer patients - a systematic review

Prevalence of co-morbidity and survival among breast cancer patients - a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites

2019 PROSPERO

183. Diagnostic value of MRI combined with ultrasound for lymph node metastasis in breast cancer: a meta-analysis

Diagnostic value of MRI combined with ultrasound for lymph node metastasis in breast cancer: a meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO

184. Breast cancer and therapy related myeloid neoplasm: systematic review

Breast cancer and therapy related myeloid neoplasm: systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation

2019 PROSPERO

185. Body image in older breast cancer survivors: a systematic review

Body image in older breast cancer survivors: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g

2019 PROSPERO

186. Barriers in the management of metastatic breast cancer patients

Barriers in the management of metastatic breast cancer patients Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g

2019 PROSPERO

187. Barriers and facilitators to participation in early detection strategies of breast cancer in migrant women: a systematic review

Barriers and facilitators to participation in early detection strategies of breast cancer in migrant women: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2019 PROSPERO

188. The influence of sarcopenia in breast cancer patients: systematic review and meta-analysis

The influence of sarcopenia in breast cancer patients: systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites

2019 PROSPERO

189. Therapies for cognitive impairment in breast cancer survivors treated with chemotherapy: a systematic review and meta-analysis

Therapies for cognitive impairment in breast cancer survivors treated with chemotherapy: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2019 PROSPERO

190. Clinical value of capecitabine addition to standard adjuvant chemotherapy in early triple negative breast cancer: survival outcome from a meta-analysis of randomized controlled trials

Clinical value of capecitabine addition to standard adjuvant chemotherapy in early triple negative breast cancer: survival outcome from a meta-analysis of randomized controlled trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility

2019 PROSPERO

191. Association of night shift work and breast cancer incidence: evidences from an updated meta-analysis of prospective cohort studies

Association of night shift work and breast cancer incidence: evidences from an updated meta-analysis of prospective cohort studies Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record

2019 PROSPERO

192. Prevention of breast and cervical cancer in refugees and asylum seekers: a systematic review and meta-analysis

Prevention of breast and cervical cancer in refugees and asylum seekers: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO

193. A piggyback systematic review of the adverse effects of chemotherapy regimes in women with breast cancer

A piggyback systematic review of the adverse effects of chemotherapy regimes in women with breast cancer Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO

194. A systematic review and meta-analysis of the distress thermometer for screening distress in patients with breast cancer

A systematic review and meta-analysis of the distress thermometer for screening distress in patients with breast cancer Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2019 PROSPERO

195. Comparative effectiveness of tamoxifene, toremifene, letrozole, anastrozole and exemestane on lipid profiles in breast cancer patients: A network meta-analysis.

Comparative effectiveness of tamoxifene, toremifene, letrozole, anastrozole and exemestane on lipid profiles in breast cancer patients: A network meta-analysis. Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

196. A systematic review of the adoption of the Choosing Wisely guidelines in breast cancer surgery to reduce overutilization

A systematic review of the adoption of the Choosing Wisely guidelines in breast cancer surgery to reduce overutilization Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2019 PROSPERO

197. Nomogram for predicting the overall survival of patients with inflammatory breast cancer: A SEER-based study. (Abstract)

Nomogram for predicting the overall survival of patients with inflammatory breast cancer: A SEER-based study. Inflammatory breast cancer (IBC) is a rare malignancy that is a unique biologic subtype of breast cancer. A nomogram to predict the overall survival (OS) of IBC patients is lacking. The aim of the study was to construct and validate a nomogram to predict the OS of IBC patients based on the Surveillance, Epidemiology, and End Results (SEER) Program.Patients diagnosed with IBC between (...) analysis identified that race, age at diagnosis, breast cancer subtype, grade, N stage, M stage, radiation, chemotherapy, and surgery were significant prognostic factors for the OS. The internally and externally validated Harrell's C-indexes were 0.763 and 0.786, respectively. The calibration plots for predictions of the 1-, 3-, and 5-year OS were in excellent agreement.A nomogram was constructed to predict the OS for IBC patients based on the SEER database and to provide accurate and individualised

2019 Breast (Edinburgh, Scotland) Controlled trial quality: uncertain

198. Eribulin for Treating Locally Advanced or Metastatic Breast Cancer After One Chemotherapy Regimen: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Full Text available with Trip Pro

Eribulin for Treating Locally Advanced or Metastatic Breast Cancer After One Chemotherapy Regimen: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Eribulin is a recommended treatment option for locally advanced or metastatic breast cancer (LABC/MBC) in adults whose disease has progressed after at least two chemotherapy regimens. The National Institute for Health and Care Excellence (NICE) invited the manufacturer of eribulin (Halaven®; Eisai Ltd) to submit evidence

2019 PharmacoEconomics - open Controlled trial quality: uncertain

199. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. Full Text available with Trip Pro

Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. 31407010 2019 08 13 1569-8041 2019 Aug 13 Annals of oncology : official journal of the European Society for Medical Oncology Ann. Oncol. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative (...) advanced breast cancer. mdz215 10.1093/annonc/mdz215 Hortobagyi G N GN Stemmer S M SM Burris H A HA Yap Y S YS Sonke G S GS Paluch-Shimon S S Campone M M Petrakova K K Blackwell K L KL Winer E P EP Janni W W Verma S S Conte P P Arteaga C L CL Cameron D A DA Mondal S S Su F F Miller M M Elmeliegy M M Germa C C O'Shaughnessy J J eng Journal Article 2019 08 13 England Ann Oncol 9007735 0923-7534 IM 2019 8 14 6 0 2019 8 14 6 0 2019 8 14 6 0 aheadofprint 31407010 5548997 10.1093/annonc/mdz215

2019 Annals of oncology : official journal of the European Society for Medical Oncology Controlled trial quality: uncertain

200. A phase II randomized clinical trial of the effect of metformin versus placebo on progression-free survival in women with metastatic breast cancer receiving standard chemotherapy. (Abstract)

A phase II randomized clinical trial of the effect of metformin versus placebo on progression-free survival in women with metastatic breast cancer receiving standard chemotherapy. Pre-clinical data suggest metformin might enhance the effect of chemotherapy in breast cancer (BC). We conducted a Phase II randomized trial of chemotherapy plus metformin versus placebo in metastatic breast cancer (MBC).In this double blind phase II trial we randomly assigned non-diabetic MBC patients on 1st to 4th

2019 Breast (Edinburgh, Scotland) Controlled trial quality: predicted high